Clinical trial · Interventional
Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance
Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance: HEMATOBIO.02-IPC 2021-061
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective is to study the genomic, transcriptomic, proteomic epigenomic, metabolomic and immune mechanisms of blasts and microenvironment cells associated with IT resistance through the constitution of a collection associating blood or marrow samples from patients with LA, MDS and MPS marrow samples from patients with LA, MDS and MPS at diagnosis, during treatment and at relapse and relapse and clinical annotations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Cancer | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| experimental:Acute leukemia/myelodysplastic or myeloproliferative disease | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- experimental:Acute leukemia/myelodysplastic or myeloproliferative disease
- description
- blood sampling, bone marrow aspirate, and buccal swab
- interventionNames
- Other: experimental:Acute leukemia/myelodysplastic or myeloproliferative disease
Primary outcomes (1)
- measure
- Acute leukemia/ Myeloproliferative/ myelodysplastic syndrome cells profiling (molecular analysis, epigenetic profile, drug sensitivity profile,immunophenotyping)
- timeFrame
- up to 7 years
- description
- establishment of genomic and proteomic signatures as well as transcriptomic and metabolic profiles associated with IT resistance.
Secondary outcomes (2)
- measure
- to study the resistance to treatments
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosis of acute leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) or myeloproliferative syndrome according to the WHO classification 2016, 2. Patient for whom a new line of therapy is initiated. 3. Patient older than 18 years of age. 4. Patient affiliated to the social security system or benefiting from such a system. 5. Signed consent to participate. Exclusion Criteria: 1. Weight at inclusion \< 50 kg 2. Participating in another clinical study that would cause the total amount of blood collection to exceed the and endanger the patient 3. Person in an emergency situation, adult under legal protection (guardianship, curatorship, etc.) protection (guardianship, curatorship or safeguard of justice), or unable to express his or her consent. 4. Impossibility to submit to the medical follow-up of the trial for geographical social or psychological reasons, 5. Pregnant or breastfeeding women
References
Publications (0)
Data not yet available